The study of periositin, a new biomarker of idiopathic pulmonary fibrosis

• Project/Area Number: 16K09567
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Kurume University
• Principal Investigator: Masaki Okamoto 久留米大学, 医学部, 講師 (50352133)
• Co-Investigator(Kenkyū-buntansha): 星野 友昭 久留米大学, 医学部, 教授 (00261066)
• Project Period (FY): 2016-04-01 – 2019-03-31
• Project Status: Completed (Fiscal Year 2018)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 特発性肺線維症 / ペリオスチン / バイオマーカー / コンパニオン診断薬

Outline of Final Research Achievements

We first reported that periostin is a potential prognostic biomarker for　predicting the short-term progression of IPF patients in previous report.　However, periostin is not a specific biomarker for IPF because it is　upregulated in various diseases other than IPF. We found that new ELISA kit detecting monomeric form of periostin can be predict pulmonary function decline and diagnosis of IPF patients.
We tried to prove that monomeric periostin can predict the therapeutic effect of nintedanib by multicenter study at 20 facilities nationwide.
This study will completed the observation period and will be conducting data analysis within 2019.

Academic Significance and Societal Importance of the Research Achievements

特発性肺線維症に特異的なバイオマーカーである単量体ペリオスチンが、本症の増悪や抗線維化薬であるニンテダニブの治療効果を予測するバイオマーカーであることを証明することによって、個別化医療の実現に寄与する可能性がある。

Research Products

• [Journal Article] Ability of Periostin as a New Biomarker of Idiopathic Pulmonary Fibrosis. (2019)
  • Author(s): Okamoto M, Izuhara K, Ohta S, Ono J, Hoshino T.
  • Journal Title: Adv Exp Med Biol Volume: 1132 Pages: 79-87
  • DOI: 10.1007/978-981-13-6657-4_9
  • ISBN: 9789811366567, 9789811366574
• [Journal Article] Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. (2018)
  • Author(s): Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, Nakamura M, Zaizen Y, Nouno T, Koga T, Kawayama T, Kuwana M, Ida H, Hoshino T.
  • Journal Title: Respir Investig Volume: 56 Issue: 6 Pages: 464-472
  • DOI: 10.1016/j.resinv.2018.07.007
  • Peer Reviewed
• [Journal Article] The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis (2017)
  • Author(s): Ohta S, Okamoto M, Fujimoto K, Sakamoto N, Takahashi K, Yamamoto H, Kushima H, Ishii H, Akasaka K, Ono J, Kamei A, Azuma Y, Matsumoto H, Yamaguchi Y, Aihara M, Johkoh T, Kawaguchi A, Ichiki M, Sagara H, Kadota JI, Hanaoka M, Hayashi SI, Kohno S, Hoshino T, Izuhara K
  • Journal Title: PloS one Volume: 12 Issue: 3 Pages: e0174547-e0174547
  • DOI: 10.1371/journal.pone.0174547
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Presentation] 先端医学研究シンポジウム「間質性肺炎急性増悪の病態および新規治療」 IPF急性増悪、抗MDA5抗体陽性ILDの病態 (2019)
  • Author(s): 岡元 昌樹
  • Organizer: 第59回日本呼吸器学会学術講演会
  • Invited
• [Presentation] シンポジウム「診断UP TO DATE～より的確な治療にむけて～」 びまん性肺疾患のバイオマーカー (2018)
  • Author(s): 岡元 昌樹
  • Organizer: 第81回日本呼吸器学会九州地方会秋季学術講演会
  • Invited
• [Presentation] 新規Periostin ELISAシステムを用いた肺線維症特異的バイオマーカーの探索研究 (2017)
  • Author(s): 岡元 昌樹
  • Organizer: 第57回日本呼吸器学会学術講演会
• [Presentation] 新規Periostin ELISAシステムを用いた肺線維症特異的バイオマーカーの探索研究 (2017)
  • Author(s): 岡元 昌樹, 他
  • Organizer: 第57回日本呼吸器学会学術講演会
  • Place of Presentation: 東京国際フォーラム
• [Book] バイオマーカー; ペリオスチンの可能性 (2017)
  • Author(s): 岡元 昌樹
  • Total Pages: 7
  • Publisher: 科学評論社